Education
About Us
Working with TipRanks
Follow Us
Maravai Lifesciences Holdings (MRVI)
NASDAQ:MRVI
Earnings Data
Report Date
May 12, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.07Last Year’s EPS
-0.02Same Quarter Last Year
Moderate Buy
Based on 10 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 18, 2025
|% Change Since: -8.53%
|Next Earnings Date:May 12, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted Maravai's strategic expansions and product launches, which lay a strong foundation for future growth. However, significant challenges were noted, including a goodwill impairment charge, a revenue recognition error, a decline in adjusted EBITDA, and no commitments for high-volume CleanCap for 2025. These challenges create uncertainty for the upcoming year, despite the company's strong cash position and strategic acquisitions.Company Guidance
During Maravai LifeSciences' earnings call for the fourth quarter of fiscal year 2024, several key financial metrics and guidance for 2025 were discussed. The company reported fourth-quarter revenues of $57 million, falling near the midpoint of their expectations. For the full year, revenues reached $259 million, aligning closely with the projected range of $255 million to $265 million. The biologic safety testing segment contributed $15 million in Q4 and $63 million for the year, while the nucleic acid production segment reported $42 million in Q4 and $196 million for 2024. Adjusted EBITDA was a negative $1 million in Q4, with the full year's adjusted EBITDA at $36 million, resulting in a 14% margin. Maravai ended the year with $322 million in cash and $300 million in long-term debt, leading to a net cash position of $22 million. The company plans to focus on its base business for 2025, anticipating revenues between $185 million and $205 million, excluding high-volume CleanCap sales due to the absence of binding commitments from major customers. They expect capital expenditures to decrease significantly to $15 million to $20 million, with further reductions anticipated in 2026.Revenue Achievement
Fourth quarter revenues were $57 million, and full-year revenue reached $259 million, which was near the midpoint of the company's stated revenue range.
Strong Cash Position
Maravai ended the year with $322 million in cash and a $22 million net cash position after voluntarily paying down $228 million of the term loan.
Facility Expansion and Product Launches
Completed multiyear facility expansions and launched approximately 50 new products, reinforcing the foundation for future growth.
Strategic Acquisitions
Acquired complementary assets from Officinae Bio and Molecular Assemblies, expected to enhance capabilities in the life science tool space.
Innovative New Products
The launch of CleanScribe and other new products gained traction, showing promise for increased market adoption.
---
MRVI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
MRVI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 18, 2025 | $2.58 | $2.43 | -5.81% |
| Nov 07, 2024 | $7.84 | $5.08 | -35.20% |
| Aug 07, 2024 | $9.10 | $8.48 | -6.81% |
| May 08, 2024 | $8.87 | $9.86 | +11.16% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Maravai Lifesciences Holdings (MRVI) report earnings?
Maravai Lifesciences Holdings (MRVI) is schdueled to report earning on May 12, 2025, TBA Not Confirmed.
What is Maravai Lifesciences Holdings (MRVI) earnings time?
Maravai Lifesciences Holdings (MRVI) earnings time is at May 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MRVI EPS forecast?
MRVI EPS forecast for the fiscal quarter 2025 (Q1) is -0.07.
---